Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Saw him last in the Yappn Corp board.
Thank you so much I enjoy your posts as well.
Hoping we all get that real GOLD fever we all deserve for sticking it out especially while participating on this mb.
I fell new highs coming today, make it stop! Lol
Based on this news and what's coming in the pipeline I think we see 3 to 4 dollars per share shortly!
Big News Out!
Milestone Scientific Receives CE Mark Approval for Intra-Articular Instrument
LIVINGSTON, NJ--(Marketwired - September 15, 2014) - Milestone Scientific Inc. (OTCQB: MLSS), a medical R&D company that designs, patents, incubates and commercializes a growing portfolio of innovative injection technologies, today announced that its subsidiary, Milestone Medical, has received CE Mark regulatory approval to market and sell its intra-articular instrument in Europe.
Leonard Osser, Chief Executive Officer of Milestone Scientific stated, "Receipt of regulatory approval in Europe for this instrument is validation of our technology and allows our subsidiary to move forward with its plans to commercialize the technology in Europe. Our subsidiary is now in the process of evaluating potential strategic partners to distribute its intra-articular instrument in Europe. We believe we are well positioned to enter this multi-billion dollar market since conventional injections are painful, a problem eliminated with our instrument, and not always efficacious, as doctors often fail to locate the intra-articular space or use inappropriate volumes of hyaluronic acid."
Milestone's injection technology is based on a patented Dynamic Pressure Sensing® system (DPS®), intended to measure the density of body tissue and thus help a clinician know the location of a hypodermic needle during an injection. The system utilizes computer controlled technology to provide real-time feedback to the medical practitioner and identify with precision when a needle has reached the location where a drug should be administered to a patient. It has the added advantage in other applications of controlling the pain that patients typically associate with injections.
About Milestone Scientific Inc.
Milestone Scientific Inc. (MLSS) is a leading medical research and development company that designs and patents innovative injection technology. Milestone's computer-controlled systems make injections precise, efficient, and virtually painless. For more information please visit our website: www.milestonescientific.com.
Safe Harbor Statement
This press release contains forward-looking statements regarding the timing and financial impact of Milestone's ability to implement its business plan, expected revenues and future success. These statements involve a number of risks and uncertainties and are based on assumptions involving judgments with respect to future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond Milestone's control. Some of the important factors that could cause actual results to differ materially from those indicated by the forward-looking statements are general economic conditions, failure to achieve expected revenue growth, changes in our operating expenses, adverse patent rulings, FDA or legal developments, competitive pressures, changes in customer and market requirements and standards, and the risk factors detailed from time to time in Milestone's periodic filings with the Securities and Exchange Commission, including without limitation, Milestone's Annual Report for the year ended December 31, 2013. The forward looking statements in this press release are based upon management's reasonable belief as of the date hereof. Milestone undertakes no obligation to revise or update publicly any forward-looking statements for any reason.
Contact:
David Waldman or Natalya Rudman
Crescendo Communications, LLC
Email: mlss@crescendo-ir.com
Tel: 212-671-1020
Source: Marketwired (September 15, 2014 - 7:30 AM EDT)
News by QuoteMedia
Good morning team USPR!
Hoping to rock and roll this week!
GLTA longs
If the news doesn't come until the end of the week I think it will be higher than .50 cent prior to the news IMHO.
Who cares?
Dam iphone sorry for the grammar errors!
If anyone else wants in on this winner now is most likely your last time to buy at the .30 level.
Based in the letter from the chairman there is the possibility to see results prior to Mondays open.
Pull the trigger don't be left saying I woulda, coulda, shoulda.
Just read the posts from today the risk reward is in out favor.
Adrock out
Glia and have a great weekend! I know I will.
I'll read for the rest of my life as long as we stay on this pace.
Black beard your correct this is some report for imaginary land.
Thanks vudu for the light reading!!!
I'm not an expert in reading these reports, can you put a numerical value I what you believe you see from these numbers without plasma being in the mix and what it jumps too if plasma tech was used usprinvestor?
Agreed
I agree with you but a rally would be nice as well!
Why?
I like to see profits.
Anyone else think we get a rally into the close?
BULLSHIT!!
Can't get any at .276
News out
Titan Medical Inc. Appoints Dr. Dennis Fowler as Executive Vice President, Clinical and Regulatory Affairs
TORONTO, ONTARIO--(Marketwired - Sept. 9, 2014) - Titan Medical Inc. ("Titan" or the "Company") (TSX VENTURE:TMD)(OTCQX:TITXF) today announced that Dr. Dennis Fowler, who currently serves as the Company's Director of Clinical Affairs, has been appointed to the newly-created position of Executive Vice President, Clinical and Regulatory Affairs.
In his new role, Dr. Fowler will be responsible for all of Titan's clinical and regulatory affairs, including pre-clinical testing and clinical development. He will also oversee Titan's U.S. and international regulatory pathways for the Company's Single Port Orifice Robotic Technology (SPORT™) Surgical System. He will work closely with the clinical and regulatory departments of Ximedica, a premier product development firm for the medical industry partnered with Titan.
"Dr. Fowler has made invaluable contributions to the development of our technology. He has led the surgical advisory boards of several companies that successfully commercialized significant healthcare products," said John Hargrove, Chief Executive Officer of Titan. "We are excited to have someone with his demonstrated technical expertise, experience and leadership skills guiding our clinical and regulatory efforts as we continue the development of SPORT™."
Dr. Fowler commented, "I am very pleased to be part of the Titan team and look forward to continuing to contribute to the development and commercialization of the SPORT™ Surgical System."
Dr. Fowler has been Director of Clinical Affairs at Titan since September 2013. Prior to that, he was a consultant to the Company. He is a co-inventor of the single-incision Insertable Robotic Effector Platform (IREP) technology, which was licensed from Columbia University for use in Titan's SPORT™ Surgical System.
Formerly, he was the Gerald and Janet Carrus Professor of Surgical Science and Director of the Center for Innovation and Outcomes Research in the Department of Surgery, Columbia University College of Physicians and Surgeons. Among other former positions, he was V.P.-Medical Director of Perioperative Services at New York Presbyterian Hospital/Columbia. In addition to his clinical, research, teaching, and administrative responsibilities, he has been the recipient of numerous honors and is a well-established author of many scientific publications.
Dr. Fowler received his M.D. in 1973 from the University of Kansas School of Medicine and received his Master of Public Health in 2008 from Columbia University, Mailman School of Public Health. He is certified by the American Board of Surgery and is a Fellow and former Governor-at-Large of the American College of Surgeons. He has held numerous leadership positions and roles in the Society of American Gastrointestinal and Endoscopic Surgeons (SAGES), the Fellowship Council, the American Board of Surgery, and is currently President of the Foundation for Surgical Fellowships.
About Titan Medical Inc.
I agree but let's get the news already to support out view.
Titan Medical Inc. Announces DTC Eligibility
TORONTO, ONTARIO--(Marketwired - Sept. 3, 2014) - Titan Medical Inc. ("Titan" or the "Company") (TSX VENTURE:TMD)(OTCQX:TITXF) announced today that the Depository Trust Company (DTC) has approved the Company's eligibility application for Titan Medical Inc. (CUSIP 88830X108), effective August 21, 2014.
The DTC, a subsidiary of the Depository Trust & Clearing Corporation (DTCC), manages the electronic clearing and settlement of publicly-traded companies. Securities that are eligible to be electronically cleared and settled through the DTC are considered "DTC eligible." This electronic method of clearing securities expedites the receipt of stock and cash, and, thus, accelerates the settlement process for investors and brokers.
"DTC eligibility increases the efficiency and lowers the costs associated with trading Titan's shares on the OTCQX, while increasing security and lowering transaction risk for our investors," said John Hargrove, Chairman and Chief Executive Officer of Titan. "Securing DTC eligibility reflects our ongoing efforts to support our growing investor base in the U.S."
About Titan Medical Inc.
Titan Medical Inc. is a Canadian public company (TSX VENTURE:TMD) (OTCQX:TITXF) focused on the design and development of a robotic surgical system for application in minimally invasive surgery ("MIS"). The Company's robotic surgical system, currently under development, comprises a surgeon-controlled robotic platform that includes a 3D vision system and interactive instruments for performing MIS procedures, and a surgeon workstation that provides the surgeon with an interface to the robotic platform for controlling the interactive instruments and providing a 3D endoscopic view of inside a patient's body during MIS procedures. The robotic surgical system is being designed to expand robotic surgery into areas of surgical specialties and simple and complex procedures that are currently under-serviced, and to allow surgeons to perform procedures within small to medium size surgical spaces such as general surgery and cholecystectomy. For more information, visit the Company's website at www.titanmedicalinc.com.
Forward Looking Statements
This news release contains "forward-looking statements" which reflect the current expectations of management of the Company's future growth, results of operations, performance and business prospects and opportunities. Wherever possible, words such as "may", "would", "could", "will", "anticipate", "believe", "plan", "expect", "intend", "estimate", "potential for" and similar expressions have been used to identify these forward-looking statements. These statements reflect management's current beliefs with respect to future events and are based on information currently available to management. Forward-looking statements involve significant risks, uncertainties and assumptions. Many factors could cause the Company's actual results, performance or achievements to be materially different from any future results, performance or achievements that may be expressed or implied by such forward-looking statements, including, without limitation, those listed in the "Risk Factors" section of the Company's Annual Information Form dated April 4, 2014 (which may be viewed at www.sedar.com). Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward looking statements prove incorrect, actual results, performance or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. These factors should be considered carefully and prospective investors should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in the news release are based upon what management currently believes to be reasonable assumptions, the Company cannot assure prospective investors that actual results, performance or achievements will be consistent with these forward-looking statements.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Titan Medical Inc.
John Hargrove
Chairman and Chief Executive Officer
(416) 548-7522 (ext. 151)
john.hargrove@titanmedicalinc.com
Titan Medical Inc.
Investor Relations
info@titanmedicalinc.com
Lurker thanks for the input but I have to say it makes sense more than a 20,000 a month contract allowing you to add two additional positions at the firm, after overhead and taxes prior to the hires we're not talking about a lot of money here.
Also based on what this firm was looking to do in the past I think the board may be onto something here.
You have to admit it does make perfect sense.
Red thanks for your input unfortunately without knowing the results no one can predict where the stock price will be in the next 30 days so most relevant at this point would be the results.
If they are what we are hoping for the stock price is going UP from here.
Glta
Great info thanks
Still haven't heard from many please post your vote for whether the reserves will be announced this week. It would be great to post the votes prior to the open on Tuesday
Ok I hear you and respect your opinion.
Jet man what's you vote please?
I would like anyone who has posted on this board over the last two years to vote whether you own the stock or not. Let's see what everyone thinks.
So far 2 yes and 0 no.
Let's take a vote yay or nay that the reserves will be announced this coming week after Labor Day.
My vote is yay. It's time.
The trend is our friend right now, and we are trending green, soon when the reserves are released we will being seeing GOLD.
Hopefully BILLIONS OF IT!
Glta
Looks to me like we will rally into the close the way the markets makers are setting up.
Three stooges very quite today! Lmao the bank.
I'm curious to see if there is follow through at the open today, if there is that would be an extremely bullish sign and may mean more good times ahead.
It's actually great I would much rather they hit milestones in a hot sector.
Stock would perform that much better, in any event it looks real good and those that sold the top to buy back may be forced to do so shortly.
One good pr and this thing is in the 3'a IMHO an we all know that.
Looks more like the entire sector was up today to me.
The number will tell us what's going on, if they are what we are hoping for executing a sale won't be difficult.
Let's just hope the number are beyond good, we all (well some) are invested literally in a gold mine!
And If that holds true we are a dollar plus stock IMHO.
If we get a report of 20 billion plus in precious metals and your a shareholder that feels the stock price won't appreciate past 40 cents something tells me you should either sell the stock as the risk reward is too small or put your money to work elsewhere.
I do believe that some will sell on news but I also believe this will be above a dollar per share simply based on this huge huge news if and when it comes IMHO.
I also believe that's rather than doing all the testing it will take to sell this for full value will not be done and that it will rather be sold at a slight discount so the people that discovered this will be able to cash out and move from Marlboro to Boca and eat a lot of steak and lobster at NY prime.
Ok I'm done and now hungry.
I agree 100 percent!
Five minutes left to buy in if the news come out pre open tomorrow.
Just ignore them one side is going to be correct and hope it's ours!!!